MORE►
FDA approval
[Image: sudok1/istockphoto]
Alpha Cognition Inks $44M Deal With China’s CMS to License Alzheimer’s Drug in Asia and Beyond
by David Seeley | Jan 9, 2025
Alpha Cognition’s Alzheimer’s oral therapy ZUNVEYL, FDA-approved in July, targets U.S. launch in Q1 2025 as the company boosts its commercialization team with five new hires.
by Lance Murray |
Nov 6, 2024
Caris said MI Cancer Seek will be used as a companion diagnostic to identify cancer patients who may benefit from treatment with targeted therapies.
MORE►
by Lance Murray |
Jul 29, 2024
“The approval of ZUNVEYL is a pivotal moment in the fight against Alzheimer's disease as it's only the second oral AD treatment to be approved in more than a decade," said CEO Michael McFadden of Alpha Cognition. Based in Vancouver with an office in Frisco, the company was honored at the 2023 BioNTX iC3 Summit as one of eight "Rising Stars."
MORE►
by David Seeley |
Jun 29, 2023
Reata cleared the final FDA hurdle to get its rare-disease drug Skylarys on the market, the company announced Tuesday. The drug is now available to U.S. patients who've been diagnosed with Friedreich’s ataxia—a genetic disorder that can cause progressive damage to the nervous system. The announcement marks Reata’s first drug approval since the company was founded in 2002, according to the Dallas Morning News.
MORE►
